Investigating how hydrogen sulfide affects Duchenne muscular dystrophy
Contribution of hydrogen sulfide to Duchenne muscular dystrophy pathophysiology
This study is looking at how a gas called hydrogen sulfide might help protect muscles in people with Duchenne muscular dystrophy (DMD), a condition that causes muscle weakness, by testing it in animals to find out if it can improve muscle function and reduce damage.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project ID | NIH-10997019 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of hydrogen sulfide in Duchenne muscular dystrophy (DMD), a severe neuromuscular disease that leads to muscle weakness and heart issues. The study will utilize an animal model to explore how the absence of dystrophin affects muscle function and how hydrogen sulfide supplementation may protect against muscle damage. By examining the mechanisms behind muscle contractility and the impact of reactive oxygen species, the research aims to uncover new insights that could lead to better treatments for patients with DMD.
Who could benefit from this research
Good fit: Ideal candidates for this research are young boys diagnosed with Duchenne muscular dystrophy, typically between the ages of 3 and 5.
Not a fit: Patients with other forms of muscular dystrophy or those who are significantly older than the target age group may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that improve muscle function and quality of life for patients with Duchenne muscular dystrophy.
How similar studies have performed: Previous research has shown promising results with hydrogen sulfide in protecting muscle function in animal models, indicating potential for success in this area.
Where this research is happening
Minneapolis, United States
- University of Minnesota — Minneapolis, United States (Active)
Researchers
- Principal investigator: Fallon, Katherine Sage — University of Minnesota
- Study coordinator: Fallon, Katherine Sage
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.